Tirzepatide Shrinks Heart Muscle Mass and Surrounding Fat in Obese Patients With Heart Failure

This was a substudy of the SUMMIT randomized controlled trial. 175 patients with obesity-related HFpEF underwent cardiac MRI at baseline, with 106 completing scans at both baseline and 52 weeks. Patients received tirzepatide (starting at 2.5 mg weekly, increasing to a maximum of 15 mg weekly via subcutaneous injection) or placebo. Researchers measured heart muscle mass, chamber volumes, and fat around the heart using multi-angle MRI sequences.

Obesity-related heart failure is a growing health crisis, and excess fat around the heart worsens cardiac function. This study provides imaging evidence that tirzepatide doesn't just help with weight loss — it directly reduces harmful structural changes in the heart. These findings help explain why tirzepatide reduced heart failure events in the main SUMMIT trial.

GLP-1/GIP receptor agonists like tirzepatide are reshaping treatment for obesity and its complications. This cardiac imaging substudy adds to a growing body of evidence that these peptide therapies provide benefits beyond weight loss, including direct improvements to heart structure. As obesity-related heart failure becomes more prevalent, understanding how these drugs remodel the heart could guide treatment strategies.

The substudy included only 106 of the 731 patients from the parent trial, limiting statistical power. The study was not powered to detect changes in clinical outcomes like hospitalizations or death. Image quality issues excluded some participants. The 52-week follow-up may not capture long-term effects, and the correlation between weight loss and cardiac changes makes it difficult to determine whether tirzepatide has direct cardiac effects independent of weight loss.